A Phase 2 to Evaluate the Dose-Response Relationship and Safety of JTT-751 in Patients with Iron Deficiency Anemia
Phase 2
Completed
- Conditions
- Iron deficiency anemia
- Registration Number
- JPRN-jRCT2080223256
- Lead Sponsor
- Japan Tobacco Inc.
- Brief Summary
The efficacy and safety results suggested that JTT-751 was expected to be clinically useful for patients with iron deficiency anemia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 147
Inclusion Criteria
Iron deficiency anemia
Hemoglobin level of= > 7.0 g/dL and < 11.0 g/d
Exclusion Criteria
Anemia caused by other than iron deficiency
Serum phosphate < 2.5 mg/dL
Uncontrollable treatment potentially affecting bleeding in patients with bleeding lesion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy<br>Changes in hemoglobin level
- Secondary Outcome Measures
Name Time Method efficacy<br>Changes in erythrocyte- and iron-related test values